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Abstract Human mitochondria can be studied either in
biopsies or by measuring flux through ATP synthase and
phosphocreatine recovery using magnetic resonance spec-
troscopy. Myocellular ATP production (flux through ATP
synthase [fATP]) increases by up to 90% during 8 h of
insulin stimulation. Fasting mitochondrial function is 14–
40% lower than in controls in the presence of insulin
resistance, as seen in those with type 2 diabetes, their
insulin-resistant relatives or the obese. Insulin-stimulated
fATP is abolished in insulin-resistant relatives and patients
with type 2 diabetes, and patients frequently show decreased
mitochondrial size/density. Age, fat mass, physical activity,
plasma NEFA and glucose all correlate negatively with
mitochondrial function, but it is for methodological reasons
difficult to determine whether reduced mitochondrial content
or function account for reduced ATP production in insulin
resistance. Experimental plasma NEFA elevation appears to
inhibit mitochondrial function by interfering with the
metabolic actions of insulin, which might explain impaired
mitochondrial function in obesity. Alternatively, primary
mitochondrial abnormalities, as seen in those with inherited
risk of type 2 diabetes, could decrease lipid oxidation,
thereby raising circulating and intracellular NEFA levels. In
type 2 diabetes, chronic hyperglycaemia and dyslipidaemia
could first diminish the function, and subsequently reduce
the size or density of mitochondria via oxidative stress
and apoptosis. Many questions remain unsolved, including
(1) which mechanisms regulate mitochondrial adaptation to
nutrient overload; (2) what factors control the expression of
genes encoding mitochondrial proteins and other signals
involved in mitochondrial biogenesis; (3) which geno/
phenotypes are associated with both insulin resistance and
mitochondrial abnormalities; and (4) which are the most
promising targets for improving mitochondrial fitness in
insulin resistance?
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Abbreviations
AMPK AMP-activated protein kinase
AV arteriovenous
CPT-1 carnitine palmitoyltransferase-1
fATP flux through ATP synthase
LCFA-CoA long-chain fatty acyl-CoA
NMR nuclear magnetic resonance spectroscopy
mtDNA mitochondrial DNA
pO2 partial pressure of O2
PET positron emission tomography
PGC-1α peroxisome proliferator-activated receptor γ
coactivator 1α
Pi inorganic phosphate
ROS reactive oxygen species
TCA tricarboxylic acid
UCP-3 uncoupling protein-3
VO2max maximum rate of O2 uptake
Diabetologia (2008) 51:2155–2167
DOI 10.1007/s00125-008-1153-2
J. Szendroedi :M. Roden
First Medical Department, Hanusch Hospital (Teaching Hospital
of the Medical University of Vienna),
Vienna, Austria
J. Szendroedi :M. Roden
Karl-Landsteiner Institute for Endocrinology and Metabolism,
Vienna, Austria
M. Roden (*)
Institute for Clinical Diabetology, German Diabetes Center and
Department of Medicine/Metabolic Diseases,





Mitochondria subserve vital processes such as substrate
oxidation and energy conversion into ATP, and play an
essential role in cellular proliferation, apoptosis and sig-
nalling by modulating production of nitric oxide, reactive
oxygen species (ROS) and intracellular calcium. Skeletal
muscle plays a major role in whole-body energy metabolism,
and is responsible for at least 80% of insulin-stimulated
glucose disposal during the euglycaemic–hyperinsulinaemic
clamp. In states of insulin resistance, impaired insulin-
stimulated glucose transport and/or phosphorylation, togeth-
er with reduced glycogen synthesis, account for more than
50% of the reduction in whole body glucose disposal [1, 2].
Skeletal muscle is primarily responsible for overall insulin
resistance and contributes to atherogenic dyslipidaemia and
hepatic insulin resistance [3, 4]. Consistent with the view
that muscle promotes the conversion of energy from ingested
carbohydrate into de novo hepatic lipogenesis and increased
lipoprotein production [3, 4], insulin resistance could be
caused by impaired mitochondrial fitness or result from
increased lipid availability from lipolysis or a high-energy
diet. Insulin resistance may also result from increased storage
of intracellular triacylglycerol (otherwise known as ectopic
fat) in tissues that normally contain negligible amounts, such
as intramyocellular lipids and hepatocellular lipids. Increased
lipid availability will give rise to intracellular lipid metabo-
lites such as long-chain fatty acyl-CoA (LCFA-CoA) which
stimulate inflammatory pathways that interfere with insulin
signal transduction, ultimately leading to insulin resistance [5].
The principal metabolic defect in skeletal muscle by which
ectopic lipids accumulate might also be a defect in muscular
fatty acid oxidation rather than oversupply of substrate [6].
Hyperglycaemia and impaired inhibition of lipolysis resulting
from insulin resistance induced glucolipotoxicity which
initiates a vicious cycle of metabolic decompensation, espe-
cially in association with a sedentary lifestyle and high-fat
diet [7]. Reduced mitochondrial function and lipid oxidation
would thus give rise to intramyocellular lipid formation and
insulin resistance, causing further impairment of mitochondrial
function.
This review summarises recent findings in humans
concerning muscle energy metabolism, insulin resistance
and the mechanisms of adaptive compensation for environ-
mental or inherited factors which predispose to the
development of type 2 diabetes.
Methods for studying mitochondria in humans
Several approaches have been developed to examine human
mitochondria, ranging from morphometry and enzymology
to functional analysis.
Morphometry
Confocal fluorescence microscopy has shown that mito-
chondria form a highly organised network within the
sarcomeres of human skeletal muscle [8], which most
probably undergoes persistent fusions and fissions. Enzyme
histochemistry can be used to identify mitochondriopathies
through measurement of NADH, ATPase or cytochrome
oxidase, and to diagnose deficiencies in mitochondrial
proliferation through measurement of succinate dehy-
drogenase. Electron microscopy allows quantification of
mitochondrial density and size and analysis of their
distribution between the subsarcolemmal and intermyofi-
brillar space. Moreover, this technique gives a picture of
branching, which is a marker of fusion–fission activity and
the morphology of the inner mitochondrial membrane.
Furthermore, abnormalities such as paracrystalline inclu-
sions, typical of mitochondriopathies, and vacuoles, often
seen in obesity and type 2 diabetes, can be detected and
probably represent degenerative processes [9]. An increase
in computational power permitted the delineation of the
crystal structures of the mitochondrial membrane com-
plexes II–V by means of x-rays [10], furthering our
understanding of structural–functional relationships.
Ex vivo functional analyses
Mitochondrial function can be studied by measuring the
activities of enzymes involved in the respiratory chain and
substrate oxidation and by more functional methods which
monitor ATP production by bioluminescent techniques or
O2 consumption with high-resolution respirometry.
Mitochondrial enzyme activities The mitochondrial electron
transport chain includes coenzyme Q, cytochrome c and
complexes I–V, which are encoded by both nuclear and
mitochondrial DNA (mtDNA), and catalyse energy trans-
duction from substrates to the proton gradient for ATP
synthesis. A number of approaches for measurement of the
corresponding enzyme activities have been reported [11].
Spectrophotometric assays measure enzyme activities per
sample protein mass, reflecting enzyme abundance in the
presence of substrate excess using specific inhibitors.
In general, cytochrome c, oxidase II and mitochondrial
membrane potential serve as a measure of electron transport
chain activity, and the activity of β-hydroxyacyl-CoA
dehydrogenase acts as an indicator of β-oxidation [12].
Citrate synthase activity is a marker of the nuclear expression
of genes encoding mitochondrial proteins and a measure of
tricarboxylic-acid (TCA) cycle activity. Because expression
of the gene encoding citrate synthase can increase following
acute exercise or insulin stimulation, stimulation of mito-
chondrial biogenesis might be more reliably determined by
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measuring mtDNA content relative to nuclear DNA, which is
not sensitive to acute metabolic changes [12].
Mitochondrial ATP production and oxygen consumption
ATP production can be quantified in suspensions of isolated
mitochondria using a bioluminescent technique that
involves luciferin–luciferase ATP monitoring [13]. Recent
developments in high-resolution respirometry allow the
measurement of O2 consumption in preparations of per-
meabilised muscle fibres and isolated mitochondria [14].
This technique also permits the application of multiple
substrate–inhibitor titrations, with the aim of characterising
mitochondrial function kinetically.
Protein fractional synthesis rates Muscular mixed and
mitochondrial protein fractional synthesis rates allow
estimation of the effects of interventions on mitochondrial
biogenesis. This method combines infusion of isotopically
labelled amino acids with serial muscle biopsies and
purification of mitochondria [15]. It can only be applied to
subsarcolemmal, but not to intermyofibrillar mitochondria.
This results from the use of proteolytic enzymes, which are
required for the isolation of intermyofibrillar mitochondria
and interfere with any findings [16].
Microarray analysis and gene expression profiling Micro-
array analysis and gene expression profiling studies in
muscle biopsies screen for variables that might trigger
skeletal muscle insulin resistance, but only a few studies
have compared readouts from molecular genetic techniques
with functional properties of mitochondria in human tissue
[17, 18].
Taken together, despite the advantages of ex vivo
techniques, a number of limitations need to be considered.
First, the isolation procedure separates mitochondria from
their physiological environment. This is partly overcome by
studying intact or permeabilised cells. Second, the sensitivity
of biochemical analyses is affected by the processing of the
biopsy samples, fresh muscle being preferable to frozen
specimens. Third, maximal enzyme activities do not neces-
sarily reflect metabolic fluxes and may not be sensitive
enough to identify subtle alterations. Because of the limited
availability of human tissue biopsy samples, time resolution
for detection of dynamic changes is restricted for some
ex vivo methods. Of note, only ∼10 mg of biopsy sample
is needed for high-resolution respirometry. Also, stable
preparations permit prolonged steady-state measurements
at many different mitochondrial states, not just maximal
capacity at saturating substrate concentrations. When com-
paring measures of mitochondrial function, the observed
effects will depend not only on study design, but also on other
confounders. Notably, matching study groups for lifestyle
factors (stable dietary habits, frequency and intensity of
physical activity) and for concentrations of substrates and
hormones (e.g. glucose and insulin levels in insulin-resistant
or diabetic humans) should be mandatory.
In vivo techniques
Expired gas analysis Expired gas analysis can be per-
formed during resting (indirect calorimetery) and exercise
(spiroergometry). Indirect calorimetry provides measures
of basal energy expenditure and substrate oxidation, where-
as spiroergometry yields rates of maximum O2 uptake
(

VO2max) during exhausting exercise. Both techniques suffer
from limitations [19]. Indirect calorimetry relies on cardio-
respiratory conditions and provides sufficient accuracy for
estimating total resting energy production (mean coeffi-
cients of variation <5%), but not for assessing carbohydrate
and fat utilisation (variation ∼20%) [20]. Spiroergometry
additionally depends on the volunteers’ musculoskeletal
fitness and motivation to reach individual peak exercising
capacity [21]. Nevertheless, it is an easy-accessible tool
with which to investigate large cohorts [22].
Assessment of arteriovenous differences in O2 partial
pressure A more invasive method applies Fick’s principle
for the local determination of muscular O2 uptake as an
indirect estimate of mitochondrial function. This method
requires the measurement of blood flow by catheterisation
and calculation of regional arteriovenous (AV) differences
in O2 partial pressure (pO2) from haemoglobin O2 sat-
uration [23]. The maximum AV pO2 difference during
exercise may be produced by mitochondrial adaptation or
by other muscular (myoglobin content, capillarisation) or
systemic (blood flow stimulated by cardiorespiration and
O2 delivery to non-muscular tissues) alterations [24]. Near-
infrared spectroscopy involves similar constraints, being a
non-invasive method for the determination of the degree of
oxygenation of haemoglobin and myoglobin as parameters
of blood O2 saturation and tissue haemodynamics. It
similarly reflects the dynamic balance between O2 delivery
and extraction in the muscle capillary bed without being a
direct measure of extraction [25]. One limitation of this
method is that the signals cannot be converted into absolute
O2 saturation. Thus, relative values within a range defined
by the absorption level at rest and at maximal exercise after
ischaemia induced by an inflated cuff merely allow for
comparison of different groups [25].
Positron emission tomography Use of positron emission




non-invasive method for determining muscular perfusion
and assessing O2 and glucose uptake [26]. Tracers have
been used to identify metabolic abnormalities associated
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with either the TCA cycle (using [11C]acetate) or β-oxidation
(using [11C]palmitate) [27]. However, the use of PET scan-
ning is restricted by the high costs of the on-site cyclotrons
that are necessary for producing short-lived radio-nuclides
and by the exposure of participants to ionising radiation.
Moreover, time-course analyses are limited by tracers’ half-
lives, and assumptions have to be made for quantification
of glucose transport [28].
Nuclear magnetic resonance spectroscopy Nuclear mag-
netic resonance spectroscopy (NMR) offers a means of
monitoring biochemical fluxes of intracellular metabolites
which is non-invasive, direct and quantitative. In this
section we discuss 31P NMR and 1H NMR.
Tissues that rapidly consume ATP such as muscle and
brain generate phosphocreatine as an energy buffering
system for rapid ATP regeneration. Determination of
phosphocreatine kinetics using 31P NMR during recovery
from a bout of exercise was developed as a tool for
estimation of mitochondrial function [29]. During exercise,
phosphocreatine concentrations decrease and then rapidly
recover, yielding a time constant of the recovery rate that is
independent of work or power output [30]. As shown in
Fig. 1, this tool shows a high level of sensitivity and could be
used to identify patients with mitochondriopathies [31] and
to monitor therapeutic interventions [32]. Notably, this
technique does not determine maximal rates of ATP
synthesis rates, but rather suprabasal dynamic oxidative
capacity, since other energy consuming and producing
processes (e.g. transmembrane transportation, protein syn-
thesis, glycolysis) are maintained during phosphocreatine
resynthesis. Glycolytic ATP synthesis (anaerobic) and
oxidative phosphorylation (aerobic) provide the energy for
long-lasting muscular work and immediate ATP buffering
by the creatine kinase reaction.
Application of the magnetisation saturation transfer
experiment to the exchange between inorganic phosphate
(Pi) and γ-ATP provides a direct measurement of the uni-
directional flux through ATP synthase (fATP) [33, 34].
Steady-state Pi magnetisation is measured with selective
continuous wave irradiation of the γ-ATP resonance and
this is compared with the magnetisation following irradia-
tion placed symmetrically down-field from the Pi frequency.
The fractional reduction in Pi magnetisation is due to the
exchange of saturated γ-ATP with non-saturated Pi nuclei
(Fig. 2). The respective fractions of Pi magnetisation
measured after variable interpulse delay lengths are used to
calculate the spin lattice relaxation time for Pi. Employing the
Forsen and Hoffman equation yields the unidirectional fATP
(μmol [g muscle]−1 min−1) [34]. Combined 13C/31P NMR
can simultaneously assess oxidation/phosphorylation energy
coupling by tracing the flux through the TCA cycle by
monitoring 13C incorporation into glutamate during contin-
uous intravenous [13C]acetate infusion [35]. We recently
developed a fast localisation 31P NMR technique to quantify
fATP in human liver, which yielded an fATP of ∼30 μmol
(g liver)−1 min−1 in healthy young volunteers [36]. It should
be noted that the possible contribution of non-mitochondrial
ATP turnover in the liver needs to be taken into account
when making this calculation.
Increased hepatocellular lipid content correlates negatively
with both whole body and hepatic insulin sensitivity, and
could be the key factor in the development of insulin resistance
and type 2 diabetes [37, 38]. In the absence of alcohol intake
or other hepatotoxic agents, hepatocellular lipid accumulation
is termed steatosis or non-alcoholic fatty liver [3, 39].
Intracellular lipid deposition in liver and muscle can be
quantified by means of 1H NMR. Despite their advantages,
these techniques cannot provide an explanation as to whether
impaired function is due to alterations in individual mito-
chondria, a reduction of mitochondrial density (i.e. number
and/or size of normally functioning mitochondria), heteroge-
neity of O2 delivery, or decreased energy demand.
Mitochondrial function under physiological conditions
The fasted state
In young, lean, healthy individuals, mean unidirectional fATP
rates measured by 31P NMR range from ∼8 [40, 41] up to
12 μmol (g muscle)−1 min−1 [42, 43] (Table 1). Muscle ATP
production can be markedly reduced in healthy elderly
volunteers aged ∼70 years (fATP of ∼4±1 μmol g−1 min−1)
[40]. On the other hand, middle-aged volunteers (mean age
57 years) have a fATP (∼10±1 μmol g−1 min−1) similar to
that observed in lean younger controls (mean age 27 years)
[42, 43]. Interestingly, these middle-aged volunteers also
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Fig. 1 Time-course of phosphocreatine (PCr) recovery after exercise
employing 31P NMR in healthy volunteers (solid line), obese volunteers
(dashed line) and patients with type 2 diabetes mellitus (dotted dashed
line) and Friedreich’s ataxia (dotted line) [31, 72, 102, 103]
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than the elderly participants of the previous study (∼0.4 vs
∼0.2 mmol kg−1 min−1) (Table 1). This is in line with the
concept that the insulin resistance that emerges during
ageing is correlated with, or even results from, reduced
mitochondrial function. An age-related decline in mitochon-
drial function might be due to a reduction in overall and, in
particular, insulin-stimulated protein synthesis [43–46], or
be related to increasing body mass, insulin resistance and
physical inactivity. Adjustment for physical activity might
abolish differences in mitochondrial function between
young and older persons [47, 48], since exercise stimulates
the rate of muscle protein synthesis in both groups [49, 50].
Thus, oxidative capacity can be maintained in humans aged
up to 70 years even though mtDNA accumulates mutations
and deletions at high rates as a result of impaired DNA
repair [51] and exposure to ROS [52].
Insulin-stimulated conditions
Insulin stimulates substrate influx in skeletal muscle [53].
These transmembranous substrate gradients enhance fATP
Table 1 In vivo mitochondrial function in healthy young and elderly individuals and patients with type 2 diabetes and their relatives




(% change vs fasting)
IS hyperglycaemiab
(% change vs fasting)
Healthy young controls
ST 0.7±0.2 12±3 15±4 (+26%) [43]
ST 0.4±0.2 8±3 [40]
ST 0.6±0.1 9±2 15±3 (+60%) [42]




TCA 10±3c 96±42 [35]
Elderly controls
ST 0.4±0.1 10±3 12±2 (+11%) [43]
ST 0.3±0.1 4±3 [40]
PR 0.3±0.1 19±3e [72]
PR 32±3 [103]
Relatives of type 2 diabetic individuals
ST 0.3±0.0 (+5%) [53]
TCA 3±1c 59±17 [35]
Type 2 diabetic individuals
ST 0.3±0.1 9±2 10±3d 10±2d [43]
PR 0.2±0.1 27±12e [72]
PR 52±7 [103]
Data are presented as means±SD. Mitochondrial function was assessed by phosphocreatine recovery (PR) or fATP using saturation transfer (ST)
during 31 P NMR or by TCA cycle activity during 13 C NMR
aUnits: mmol (kg body weight)−1 min−1
b Units: for ST, μmol (g muscle)−1 min−1 ; for PR, s; for TCA, nmol (g muscle)−1 min−1
c Insulin sensitivity index (isi)
d non significant vs fasting
eMeasured at 2 h postprandially
IS, insulin-stimulated
Fig. 2 Assessment of fATP applying the saturation transfer experi-
ment during 31P magnetic resonance spectroscopy in one healthy
young volunteer. The 31P spectra were obtained during application of
selective continuous wave irradiation of the γ-ATP in vivo in the
gastrocnemius-soleus muscle complex. Sequential spectra show frac-
tional reductions in inorganic phosphate (Pi) magnetisation measured
after eight variable interpulse delay lengths ranging from 500 ms
(bottom) to 7 s. PCr, phosphocreatine
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until a new equilibrium is reached [54, 55], and this im-
mediate insulin effect on fATP might last for up to ∼4 h
[42, 43, 56]. During prolonged hyperinsulinaemia, in-
creased electron chain enzyme activities via allosteric
stimulation (starting at 1–3 h) and mitochondrial protein
production (after ∼6 h) further augment fATP [56]. Insulin
stimulation has been reported to increase fATP in muscle
mitochondria by 10–16% in vivo after 4 h and by 32–42%
in vitro after 8 h [42, 43, 53]. Use of 31P NMR in
combination with the euglycaemic–hyperinsulinaemic
clamp technique revealed that fATP increases by ∼26–
90% at 30–240 min in young, lean, healthy humans and by
∼11% at 120–240 min in insulin-sensitive elderly humans
(Table 1).
Mitochondrial function under pathophysiological
conditions
Mitochondriopathies
Most mitochondriopathies are associated with maternally
inherited mutations of mtDNA and of nuclear DNA
encoding mitochondrial proteins. Diabetes is commonly
present in mitochondriopathies resulting from impaired
glucose-stimulated insulin secretion caused by insufficient
supply of ATP and GTP [57–59]. Insulin sensitivity can be,
but is not generally, decreased in mitochondrial diabetes
[31]. We have identified one patient with MELAS
(myopathy, encephalopathy, lactate acidosis, stroke-like
episodes) syndrome with not only reduced fasting and
insulin-stimulated fATP but also insulin resistance, despite
no accumulation of intramyocellular lipid [60]. This
suggests that mitochondrial dysfunction at least contributes
to insulin resistance. Friedreich’s ataxia, another mitochon-
drial disease associated with an increased risk of diabetes,
leads to increased ROS production [31] and reduced
mitochondrial function (Fig. 1) [61]. Interestingly, in
patients with treated acromegaly fATP is reduced by
∼25% and beta cell function is impaired, indicating that
acquired endocrine alterations can also induce prolonged
mitochondrial dysfunction [62].
Insulin-resistant conditions
Cellular metabolites such as LCFA-CoA, originating from
NEFA; diacylglycerol, originating from membrane-bound
phosphatidylinositol; and ceramide, generated by sphingo-
myelin hydrolysis, inhibit insulin signalling by serine/
threonine phosphorylation of insulin receptor substrates
[5]. Many studies have provided evidence of abnormalities
in mitochondrial number/size, structure and function in
insulin-resistant states. It is as yet unclear as to whether
these alterations are primary or secondary, i.e. produced by
ageing and/or changes in endocrine and metabolic con-
ditions associated with insulin resistance.
The fasted state In patients with type 2 diabetes and uncon-
trolled glycaemia (mean HbA1c 7.5–8%), citrate synthase
activity is ∼14–20% lower than that observed in lean
healthy controls. This is consistent with a reduced cellular
mitochondrial content, but does not rule out functional
impairment [9, 63]. Of note, there was no difference in
mitochondrial function between type 2 diabetic and obese
patients [64]. Cellular mitochondrial content was reduced in
both groups, while electron transport chain activity was
diminished in subsarcolemmal mitochondria of the type 2
diabetic group only [64]. Complex I and citrate synthase
activities were ∼40% and ∼19% lower, respectively, in type 2
diabetic patients than in obese and lean healthy humans [9].
In this study, mitochondrial size and complex I activity
showed a negative relationship with insulin resistance [9].
However, these correlations were not adjusted for fat
mass, which is negatively associated with complex I
activity. These studies reported morphological abnormali-
ties in mitochondria across the whole cell, whereas enzyme
activities were predominantly assessed in the subsarcolem-
mal compartment. Of note, Ritov et al. [64] found that
complex II activity was reduced only in the subsarcolem-
mal mitochondria of patients with type 2 diabetes. On the other
hand, Boushel et al. recently demonstrated reduced complex I
and II activities in type 2 diabetes when expressed per unit
mass of skeletal muscle [65]. They concluded that mito-
chondrial function in type 2 diabetes is comparable to that
in healthy, overweight, age- and BMI-matched individuals
and that blunting of respiration in type 2 diabetes could
be attributed to lower mitochondrial content. Although
mtDNA content per tissue mass was ∼19% lower, the ratio
of mtDNA:total DNA was not altered in type 2 diabetes,
providing no evidence for reduced mitochondrial content.
In this study, type 2 diabetic patients were not compared
with young, lean individuals, thus largely excluding effects
secondary to aging and obesity. Since no measure of insulin
sensitivity was reported, effects of differences in insulin
sensitivity cannot be evaluated.
Glycolytic fast-twitch type IIb fibres generally show less
oxidative enzyme activity and higher glycolytic enzyme
activity than oxidative slow-twitch type I or oxidative fast-
twitch type IIa fibres [66]. Some groups have therefore tried
to establish whether differences in proportions of fibre
types could explain variation in mitochondrial function in
type 2 diabetes, and increased proportions of type IIb fibres
have been reported by several [67–69], though not all,
studies [70].
The observation that establishment of near-normoglycaemia
in patients with poorly controlled type 2 diabetes normalised
the transcription of genes involved in oxidative phosphory-
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lation indicates that metabolic and endocrine control affect
mitochondrial function [71]. Thus, mitochondrial function
in type 2 diabetes was found to be ‘normal’ when glucose-
lowering medication was withdrawn 1 day before the
experiment [65], but was impaired 2 weeks after with-
drawal of medication [63]. Other endocrine influences on
mitochondrial function have recently been reviewed [58].
To rule out effects of glucotoxicity, we compared the fATP
of a group of non-obese type 2 diabetic patients with good
metabolic control (mean HbA1c 6.9%) with that of a lean
young control group and an older group matched for age,
physical activity and BMI [43] (Table 1). The fATP was
∼27% lower in type 2 diabetic patients than in young
individuals and tended to be lower than in older controls.
Interestingly, these older controls had a higher fATP than
those in a previous study [40] that reported ∼50% lower
fATP compared with young controls. Only fasting plasma
NEFA and WHR, a marker of visceral adiposity, indepen-
dently predicted fasting fATP across the entire study
population (Fig. 3).
Using phosphocreatine recovery, Schrauwen-Hinderling
et al. [72] reported impaired mitochondrial function in
type 2 diabetes (mean HbA1c 7.3%) in the face of unchanged
intramyocellular lipid levels (Fig. 1, Table 1). Likewise, we
found no difference in intramyocellular lipid levels, but
hepatocellular lipid levels were four- to sevenfold higher
in type 2 diabetes than in the young and elderly control
groups [43]. Accordingly, excessive hepatic lipid storage
relates to insulin resistance, hepatocellular mitochondrial
dysmorphology, depletion of mtDNA and decreased ECT
activity [3, 73, 74]
In summary, mitochondrial function was either un-
changed or reduced and inconsistently related to measures
of insulin sensitivity in different groups of patients with
overt type 2 diabetes. In addition to differences in body fat
mass and age, variations in circulating insulin and substrate
levels limit the conclusions that can be drawn from these
data. Thus, it remains unclear at present whether impaired
mitochondrial fitness is the cause or the consequence of
insulin resistance.
To evaluate the role of mitochondrial function in inherited
insulin resistance, normoglycaemic but insulin-resistant
first-degree relatives of patients with type 2 diabetes have
been examined. These exhibit decreased muscular glucose
transport/phosphorylation and glycogen synthesis and re-
duced

VO2max. These changes are independent of habitual
physical activity, increased circulating NEFA levels, ectopic
lipid deposition and defective insulin secretion [22, 41, 75,
76]. In non-diabetic relatives of type 2 diabetic patients, a
recent DNA microarray study found that muscular per-
oxisome proliferator-activated receptor γ coactivator 1α
(PGC-1α), which activates genes controlling oxidative
metabolism, was reduced [17]. Consistent with this, another
study showed that mtDNA content was reduced in non-
diabetic relatives of type 2 diabetic patients compared with
that in individuals with no family history of diabetes, and
was related to insulin resistance and impaired switching
of substrate oxidation in response to a high-fat diet [77].
Compared with young healthy controls, insulin-resistant rel-
atives of individuals with type 2 diabetes showed decreased
cytochrome c oxidase activity (by ∼50%) and mitochondrial
density (by ∼38%), increased intramyocellular lipid levels
(by ∼60%), decreased glucose uptake (by ∼60%), increased
IRS-1-serine phosphorylation (by ∼50%) and reduced
insulin-stimulated Akt activation (by∼60%). However,
mtDNA copy number and levels of key regulators of
biogenesis, e.g. PGC-1α and -1β and nuclear respiratory
factors 1 and 2, were unaffected [78]. This is consistent
with impairment of mitochondrial function in relation to
insulin resistance, which predisposes insulin-resistant rela-
tives to intramyocellular lipid accumulation. This, in turn,
activates a serine kinase cascade, leading to defective

























































Fig. 3 a Correlation (R=0.531, p=0.002) of fATP during insulin
stimulation with insulin sensitivity (whole body glucose disposal) in
healthy young (triangles), elderly (squares) and type 2 diabetic
humans (diamonds). Correlation of and fATP at baseline with BMI
(b Spearman correlation coefficient, R=–0.826, p=0.003) and the
physical activity index (c R=0.932, p<0.001) in type 2 diabetic
humans [43]
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insulin signalling and action in muscle. The reason for the
inconsistency between these studies might relate to the fact
that the insulin-resistant relatives described in the latter
study were young, lean and healthy [78], whereas the
participants in the other studies were older, obese and
diabetic. Petersen et al. used 31P NMR and found that
insulin-resistant relatives of individuals with type 2 diabetes
have a ∼30% lower fasting fATP, ∼80% higher intra-
myocellular lipid, but similar hepatocellular lipid levels
compared with insulin-sensitive controls [41] (Table 1).
These relatives also have reduced insulin-stimulated fATP
and Pi transport into skeletal muscle, which hints at
coupling of these processes [53]. However, in contrast to
potentially inherited defects in mitochondrial biogenesis, it
is possible that these alterations result from acquired defects
such as lipid-mediated interference with insulin signalling.
In line with this, a recent analysis demonstrated that
systemic oxidative stress is related to insulin resistance in
relatives of individuals with type 2 diabetes even after
adjustment for BMI [79], but extended longitudinal studies
of individuals at risk would be needed to prove causal
relationships.
The insulin-stimulated state Ex vivo muscle biopsy studies
demonstrated that citrate synthase activity and ATP pro-
duction do not increase in obese individuals with untreated
type 2 diabetes during prolonged hyperinsulinaemic–
normoglycaemic clamps for 6–8 h [56]. To examine in
vivo mitochondrial function, we monitored fATP, glucose
transport/phosphorylation and intramyocellular lipid with
1H/31P NMR during hyperinsulinaemic–normoglycaemic
clamps for 4 h in individuals with type 2 diabetes and older
and younger control groups [43] (Table 1). The type 2
diabetic participants were non-obese, had metabolically
well-controlled diabetes and were matched to the controls
in terms of physical activity. The fATP was not affected by
insulin stimulation in the type 2 diabetic group, but was
markedly increased in both control groups. Insulin sensi-
tivity explained ∼30% of the variation in insulin-stimulated
fATP. Other contributing factors included hepatocellular
lipid and fasting plasma NEFA.
In a recent study, biopsy samples from muscles of obese
individuals with hyperglycaemic type 2 diabetes were
obtained before and 30 min after oral ingestion of 75 g of
glucose [65]. The rise in plasma glucose and insulin did
not change O2 flux rates, suggesting a defect in insulin-
stimulated mitochondrial function. Likewise, myotubes
from lean and obese, but not from type 2 diabetic,
participants responded to incubation with insulin for 4 h
with a ∼30-% increase in citrate synthase activity. Simul-
taneous addition of palmitate diminished the stimulatory
effect of insulin in myotubes from controls, suggesting that
NEFA-induced insulin resistance might interfere with
insulin-stimulated mitochondrial function [80]. To examine
the effect of increased levels of NEFA on mitochondrial
function and its relationship with lipid-induced insulin
resistance in vivo, we measured intramyocellular glucose
transport/phosphorylation by measuring glucose 6-phosphate,
fATP and intramyocellular lipid by 31P/1H NMR during
euglycaemic–hyperinsulinaemic clamp tests [42]. Short-term
elevation of plasma NEFA levels reduced the insulin-
stimulated increase in fATP similar to the impairment of
fATP reported for insulin-resistant humans [53, 56]. The
changes in intramyocellular glucose 6-phosphate were
strongly correlated with fATP, confirming the tight connec-
tion between insulin-stimulated glucose disposal and fATP.
However, lipid-induced insulin resistance and impaired
mitochondrial function were not related to intramyocellular
lipid content, suggesting that lipid deposition is not
pathogenically relevant [42].
Adaptive capacity of mitochondrial function
and mechanisms of regulation
In addition to decreased oxidative phosphorylation gene
expression, altered mitochondrial size, number, function,
localisation [9, 64, 78, 81] and generally reduced oxidative
capacity [41, 43], defective adaptation mechanisms
seem to play a pivotal role in mitochondrial dysfunction
(Fig. 4).
Metabolic flexibility
Based on the concept that the ratio of the fluxes through the
glycolytic and oxidative pathways is involved in the
plasticity of muscle metabolism [82], several groups have
consistently demonstrated a relative increase of glycolytic
(e.g. phosphofructokinase, glyceraldehyde-3-phosphate
dehydrogenase, hexokinase) over oxidative (e.g. citrate
synthase, cytochrome c oxidase) enzyme activities in obese,
physically inactive individuals, and persons with a family
history of or with overt type 2 diabetes [63, 77, 83, 84].
Reduced activation of pyruvate dehydrogenase or impaired
inhibition of carnitine palmitoyltransferase-1 (CPT1) com-
plexes by insulin are examples of molecular disturbances
that could be responsible for metabolic inflexibility [85,
86]. Similarly, the in vivo thermic effect of insulin and
glucose, as measured by indirect calorimetry, has been
reported to be blunted in insulin-resistant states, possibly
reflecting genetically reduced energy expenditure or ‘insu-
lin resistance of the mitochondria’ [87, 88]. It was later
discovered that insulin stimulates in vitro mitochondrial
function by increasing mitochondrial protein levels, thereby
augmenting mitochondrial ATP production in lean healthy,
but not in diabetic, humans [56].
2162 Diabetologia (2008) 51:2155–2167
Transport of NEFA
Production of membrane-bound fatty acid binding protein
is upregulated in the endurance-trained state, and is prob-
ably instrumental in enhancing lipid oxidation rates [89].
Inhibiting the uptake and cellular distribution of NEFA to
the sites where it is metabolised protects against insulin
resistance during lipid loading in mice lacking adipocyte-
specific fatty acid binding protein [90]. However, following
intracellular uptake, NEFA can activate AMP-activated
protein kinase (AMPK), which inactivates acetyl-CoA car-
boxylase and consequently decreases malonyl-CoA levels,
thereby increasing lipid oxidation (Fig. 4). Hence, NEFA per
se effectively facilitate intracellular lipid allocation [91, 92].
Uncoupling protein-3 (UCP-3) is expressed in human
skeletal muscle and can be induced by fasting-induced
NEFA-release and a high-fat diet. In states of excess
mitochondrial NEFA supply, LCFA-CoA accumulates and
the CoA pool in the mitochondrial matrix declines,
inhibiting oxidation of partially metabolised NEFA. UCP-3
might provide an overflow pathway for NEFA in concert
with mitochondrial thioesterase-1 (Fig. 4). Liberation of
CoA by mitochondrial thioesterase and export of NEFA
anions by UCP-3 would allow for greater rates of lipid
oxidation and reduce the membrane potential, alleviating
ROS production [93, 94].
CPT1 catalyses the rate-limiting step of NEFA transport
into the mitochondrion. Malonyl-CoA, a potent inhibitor of
CPT1, is considered a key regulator of lipid oxidation [95].
Schrauwen et al. proposed alternatively that during excess
NEFA supply, a larger fraction enters the matrix via a
transmembrane flip-flop mechanism as opposed to the
CPT1 system [96, 97] (Fig. 4). Due to a lack of acyl-CoA
synthase, NEFA would not be metabolised to LCFA-CoA,
increasing the risk of mitochondrial lipid peroxidation.
UCP-3-mediated NEFA export would protect against such
damage and mitigate ROS production, which corresponds
to the former ‘NEFA cycling model’ [98]. Echtay et al.
proposed a mechanism involving the activation of a UCP-3-
mediated proton leak by 4-hydroxynonenal, a by-product of
lipid peroxidation [99]. Thus, a negative feedback loop to
reduce the transmembrane proton-motive force would again
reduce ROS production. Hence, prolonged NEFA exposure
may result in continuous uncoupling, leading to mitochon-
drial fatigue and sustained reduction of oxidative capacity.
Impaired defence mechanisms against ROS, such as super-
oxide dismutases, catalase and a variety of peroxidases, will
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Fig. 4 Schematic diagram summarising the interaction between
lipids, insulin action and mitochondrial function in skeletal muscle.
The transporters are indicated by red borders; metabolites, no border;
enzymes, grey border; phosphorus metabolites, red type. AMPK,
AMP-activated protein kinase; DAG, diacylglycerol; FATP-1, fatty
acid transport protein 1; G6P, glucose 6-phosphate; HK-II, hexokinase II;
MT1, mitochondrial thioesterase-1; mtTFA, mitochondrial transcription
factor A; mTOR, mammalian target of rapamycin; mtProtein, mitochon-
drial protein; nDNA, nuclear DNA; NFκB, nuclear factor κB; OXPHOS,
oxidative phosphorylation;β-ox., β-oxidation; NRFs, nuclear respiratory
factors; PCr, phosphocreatine; PKC, protein kinase C; PPARs, peroxi-
some proliferator-activated receptors; S6K1, S6 kinase 1
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Hypothesis of incomplete lipid oxidation
Recently, another mechanism was proposed in which
augmented lipid uptake into mitochondria, occurring under
conditions of low PGC-1α content, leads to a mismatch of
increased β-oxidation and decreased TCA and electron
transport chain activities, triggering the accumulation of
β-oxidative intermediates. Glucose-tolerant relatives of type 2
diabetic individuals, glucose-intolerant humans and patients
with overt type 2 diabetes exhibit reduced muscular levels
of PGC-1α and oxidative phosphorylation genes, which
could determine background susceptibility for insulin
resistance. Studies employing overexpression of the gene
encoding PGC-1α suggested a shift from ‘incomplete’ to
complete β-oxidation and reversal of insulin resistance via
adaption to lipid overload [100]. Accordingly, insulin
sensitivity is closely related to fasting whole body lipid
oxidation, but not to intramyocellular lipid levels, in relatives
of individuals with type 2 diabetes [101], which further
supports the notion that impaired lipid oxidation is related
to insulin resistance. In conclusion, under conditions of
lipid overload, impaired lipid partitioning between cytosol
and mitochondria can result in progressive accumulation of
lipid metabolites and mitochondrial dysfunction.
Conclusions and outlook
Fasting mitochondrial function is not generally impaired in
insulin-resistant states, whereas insulin-stimulated fATP is
uniformly abolished in insulin-resistant relatives of and
patients with type 2 diabetes. Of note, age, fat mass, plasma
NEFA and glucose correlate negatively with mitochondrial
function. Moreover, methodological differences between
studies make it difficult to conclude whether reduced
mitochondrial fitness or insulin resistance per se account
for reduced ATP production associated with insulin-
resistant states. In this context, many studies exploring
mitochondrial function did not assess physical activity or
insulin sensitivity. It is also unclear to what extent reduced
oxidative capacity relates to the subfraction of subsarco-
lemmal mitochondria, whereas less information is available
on intermyofibrillar mitochondria because of the use of
differential centrifugation in the absence of proteases.
At present, there is evidence that well-characterised
insulin-resistant relatives of type 2 diabetic patients suffer
from abnormalities in mitochondrial number and function,
whereas patients with overt type 2 diabetes exhibit insulin
resistance in response to acute changes in mitochondrial func-
tion [43]. As the majority of type 2 diabetic patients mostly
also show increased plasma NEFA and glucose levels, these
findings support the view that these patients develop
adaptive mechanisms that improve their basal ATP turnover.
Nevertheless, many questions, including the following
remain unsolved: (1) Which mechanisms regulate mito-
chondrial adaptation to nutrient overload? (2) Which factors
control gene expression of mitochondrial proteins and
signals involved in mitochondrial biogenesis? (3) Which
geno/phenotypes are associated with both insulin resistance
and mitochondrial abnormalities? (4) Which targets are
promising for improving mitochondrial fitness in insulin
resistance?
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